The Series B financing gives Crystalys additional capital to progress its late-stage clinical programme and prepare dotinurad for potential commercialisation.

Neuropsychiatric drug developer Draig Therapeutics has raised $65 million in an oversubscribed Series B financing round to accelerate development of its pipeline, led by its investigational depression therapy DT-101.

The deal gives Bayer additional financial flexibility while allowing the company to retain operational control of its long-acting reversible contraceptives portfolio.

The new funding will accelerate manufacturing and commercial deployment of the FDA-cleared Marie system, which reimagines proton therapy by rotating the patient instead of the treatment machine.

New funding will support a pivotal Phase III trial comparing deupirfenidone head-to-head with Roche’s Esbriet as competition intensifies in idiopathic pulmonary fibrosis.

Funding will support the global SURPASS-IPF trial comparing deupirfenidone directly against standard-of-care pirfenidone in idiopathic pulmonary fibrosis.

The funding round positions Decart at the centre of the race to build AI systems capable of understanding and interacting with the physical world in real time.

Listing of anonymised health data for 500,000 participants highlights growing tension between data access, global research collaboration, and patient trust.